First-Ever Point-Of-Care COVID-19 Serology Test Granted EUA By FDA

The US agency on 23 September granted emergency use authorization for the Assure COVID-19 IgG/IgM Rapid Test Device to be used in point-of-care settings like doctor’s offices, hospitals, urgent care centers and emergency rooms. The test requires a fingerstick to draw blood.

Health Screenings: Fingerstick or Venous Blood Draw for Laboratory Hematology
The Assure POC test requires a fingerstick to draw blood

The US Food and Drug Administration on 23 September granted emergency use authorization (EUA) to Assure Tech Co. Ltd. for its point-of-care serology test for COVID-19. It’s the first POC blood test for determining whether a person has been exposed to the SARS-CoV-2 virus.

The Assure COVID-19 IgG/IgM Rapid Test Device – originally issued an EUA in July for use only in labs –...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Diagnostics

More from Device Area

  • Owkin Teams With AstraZeneca To Develop AI-Based Breast Cancer Prescreening Tool

     

    Biopharmaceutical giant AstraZeneca has partnered with start-up “unicorn” Owkin to develop an AI-powered tool to prescreen for gBRCA mutations on the basis of morphological features in digitized pathology slides. Built on extensive, high-quality data sourced from the France-based PortrAIt consortium, the AI will help to prioritize patients for further testing, streamlining the diagnostic process, Owkin says.

  • Route 92 To Drive FreeClimb Neurointervention Sales With Extended Series F Funding

     

    An additional $50m brings the neurovascular intervention specialist’s total Series F funding to $82m. Route 92 says it will use the capital to build its sales and support teams and pursue regulatory authorizations around the globe for its FreeClimb portfolio while advancing its SUMMIT MAX clinical trial for the investigational Monopoint Reperfusion System.

  • TRiCares Initiates EU Pivotal Study For Topaz Tricuspid Valve Replacement

     

    TRiCares announced first implantation of the Topaz transfemoral tricuspid heart valve replacement system as part of the company’s EU pivotal study. If all goes to plan, the device will compete with Edwards’ Evoque system. The announcement follows the company’s $50m series D funding raise in July.